02201oam 2200493I 450 991079874060332120230126214650.01-138-20421-81-315-46987-11-315-46989-810.4324/9781315469898 (CKB)3710000000885722(MiAaPQ)EBC4710148(OCoLC)962355828(EXLCZ)99371000000088572220180706e20171982 uy 0engurcnu||||||||rdacontentrdamediardacarrierThe Morning Chronicle survey of labour and the poor the metropolitan districts /Henry MayhewAbingdon, Oxon :Routledge,2017.1 online resource (257 pages)Routledge library editions. The history of social welfare ;volume 22First published in 1982 by Caliban Books.1-138-20417-X 1-315-46988-X chapter Letter LV: Thursday, June 6, 1850 -- chapter Letter LVI: Thursday, June 13, 1850 -- chapter Letter LVII: Thursday, June 20, 1850 -- chapter Letter LVIII: Thursday, June 27, 1850 -- chapter Letter LIX: Thursday, July 4, 1850 -- chapter Letter LX: Thursday, July 11, 1850 -- chapter Letter LXI: Thursday, July 18, 1850 -- chapter Letter LXII: Thursday, July 25, 1850 -- chapter Letter LXIII: Thursday, August 1, 1850 -- chapter Letter LXIV: Thursday, August 8, 1850 -- chapter Letter LXV: Thursday, August 15, 1850 -- chapter Letter LXVI: Thursday, August 22, 1850 -- chapter Letter LXVII: Thursday, August 29, 1850 -- chapter Letter LXVIII: Thursday, September 5, 1850.Working classGreat BritainPoorGreat BritainLondon (England)Social conditionsGreat BritainSocial conditions19th centuryWorking classPoor305.5620941Mayhew Henry1812-1887,168018MiAaPQMiAaPQMiAaPQBOOK9910798740603321The Morning Chronicle survey of labour and the poor3675292UNINA06266nam 2201585z- 450 991058021580332120220706(CKB)5690000000011929(oapen)https://directory.doabooks.org/handle/20.500.12854/87543(oapen)doab87543(EXLCZ)99569000000001192920202207d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to BedsideBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (296 p.)3-0365-4490-9 3-0365-4489-5 Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of DiseaseHistory of engineering and technologybicsscMaterials sciencebicsscTechnology: general issuesbicssc3D cultureamineangiotensinanimal modelanti-inflammatoryantigen releaseatorvastatin calciumbiocompatiblebiodegradableblood-brain barrier (BBB)brightnesscancercardiovascularcarrageenan induced inflammationcentral nervous systemchemoimmunotherapychitosanclinical translationconfocal microscopycoumarin 6current Good Manufacturing Practice (cGMP)Cy5.5cytotoxicitydesign of experimentsDiIdouble emulsion solvent evaporationdouble-emulsion methoddownstream processingdrug deliverydrug delivery systemdrug releasedrug release kinetics modelingdry powder inhalationemulsionencapsulationester and acid-end cappedfluorescent labelingFood and Drug Administration (FDA)H. pyloriimmune checkpoint blockadeimmunogenic cell deathin vitroin vivo neuroimagingIndomethacininline sonicationintracellular internalizationJO-4Katushkalyophilizationmas receptormethotrexatemicro-implantmicrofluidicmicrofluidicsminimally invasivemorphologynanomedicinenanoparticlenanoparticlesnanotechnologyneurodegenerative diseasesneuroprotective drugsnuclear medicineorthotopic tumorsparticle-sizePEGylationpharmacokinetics (PK) and biodistributionphotothermal therapyphthalocyaninePLA/PLGAPLGAPLGA diblock copolymerPLGA nanoparticlesPluronic triblock copolymerPNA5 glycopeptidepoly (lactic-co-glycolic acid) (PLGA)poly(lactic-co-glycolic acid)poly(lactic-co-glycolic acid) (PLGA)poly(lactic-co-glycolic) acidpoly(lactide-co-glycolide)polymeric nanoparticlespolyvinyl alcohol (PVA)porous PLGA particlesquantum yieldradiolabeled nanoparticlesrhodamine 123scale-up manufacturingsizeSKOVip-katsolid-state characterizationsolventsspheroidsstability of fluorescent labelstabilizerssucrosesustained releasetangential flow filtrationtrehaloseTurboFP635History of engineering and technologyMaterials scienceTechnology: general issuesTagit Oyaedt1313404Tagit OyaothBOOK9910580215803321Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside3031389UNINA